NewLink Genetics Corporation Company Profile (NASDAQ:NLNK)

NewLink Genetics Corporation trades on the NASDAQ under the ticker symbol "NLNK."

NewLink Genetics Corporation (NASDAQ:NLNK) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.72) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.10. The company had revenue of $2.76 million for the quarter, compared to analyst estimates of $2.68 million. NewLink Genetics Corporation had a negative net margin of 250.91% and a negative return on equity of 61.98%. View NewLink Genetics Corporation's Earnings History.

5 analysts have issued twelve-month target prices for NewLink Genetics Corporation's stock. Their predictions range from $8.00 to $32.00. On average, they anticipate NewLink Genetics Corporation's stock price to reach $22.80 in the next year. View Analyst Ratings for NewLink Genetics Corporation.

Here are some recent quotes from research analysts about NewLink Genetics Corporation stock:

• 1. According to Zacks Investment Research, "NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. " (6/9/2017)
• 2. Stifel Nicolaus analysts commented, "NLNK shares are looking increasingly actionable ahead of what we believe could prove to be a transformational next 1-6 months ' highlighted by two indoximod-related presentations at the upcoming AACR meeting and a critical mid-FY17 data disclosure from partner Roche. We believe incremental data from the P2 trial evaluating the combination of indoximod/pembrolizumab will provide an apples/apples comparison to Incyte/Merck's epacadostat/pembrolizumab P2 melanoma data ' potentially dispelling the prevailing 'I DON'T' inhibitor thesis and providing a future runway for value attribution (now made even easier with the recent filing of additional formulation-related IP). We believe P1b data from the Roche development program evaluating the combination of atezolizumab/GDC-0919 may represent the first mechanistic/translational evidence supporting the contribution of IDO inhibition to an immunotherapy-based regimen ' significantly improving visibility into a meaningful stream of future non-dilutive revenue. Target increased to $26 (previously $22)." (3/1/2017)
• 3. Jefferies Group LLC analysts commented, "NLNK plans to present more data on indoximod throughout 2017. At AACR in April there will be updated data on the pembro combo in melanoma with some baseline characteristics as well as preclinical data on the prodrug formulation of indoximod. Titles of these abstracts will be released tomorrow at 4:30pm. Additional data will be seen from the panc cancer trial combo with gem/ Abraxane in 2H17. We continue to await data from the GDC-0919 program." (3/1/2017)

Some companies that are related to NewLink Genetics Corporation include PDL BioPharma (PDLI), Agenus (AGEN), Adamas Pharmaceuticals (ADMS), Novavax (NVAX), Concert Pharmaceuticals (CNCE), Celldex Therapeutics (CLDX), Nabriva Therapeutics AG (NBRV), Curis (CRIS), Puretech Health PLC (PRTC), Idera Pharmaceuticals (IDRA), Advaxis (ADXS), Corvus Pharmaceuticals (CRVS), Codexis (CDXS), Abeona Therapeutics (ABEO), Zynerba Pharmaceuticals (ZYNE), Voyager Therapeutics (VYGR), Protagonist Therapeutics (PTGX) and Compugen (CGEN).

NewLink Genetics Corporation's management team includes the folowing people:

• Charles J. Link Jr. M.D., Chairman of the Board, Chief Executive Officer, Chief Scientific Officer
• Nicholas N. Vahanian M.D., President, Chief Medical Officer, Director
• John Bell Henneman III, Chief Financial Officer, Secretary
• Brian Wiley, Chief Commercial Officer
• Thomas A. Raffin M.D., Lead Independent Director
• Paolo Pucci, Director
• Paul R. Edick, Independent Director
• Joseph B. Saluri, Independent Director
• Ernest J. Talarico III, Independent Director

NewLink Genetics Corporation's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.29%), FMR LLC (3.10%), Columbus Circle Investors (1.17%), Driehaus Capital Management LLC (0.73%), Teachers Advisors LLC (0.71%) and Bank of New York Mellon Corp (0.69%). Company insiders that own NewLink Genetics Corporation stock include Brian Wiley, Carl W Langren, Charles J Jr Link, John B Henneman III and Joseph Saluri. View Institutional Ownership Trends for NewLink Genetics Corporation.

NewLink Genetics Corporation's stock was sold by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Renaissance Technologies LLC, TFS Capital LLC, Morgan Stanley, Piermont Capital Management Inc., Trexquant Investment LP, Alliancebernstein L.P. and Credit Suisse AG. View Insider Buying and Selling for NewLink Genetics Corporation.

NewLink Genetics Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Columbus Circle Investors, EAM Investors LLC, Ameriprise Financial Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Bank of New York Mellon Corp and Endurant Capital Management LP. View Insider Buying and Selling for NewLink Genetics Corporation.

Shares of NewLink Genetics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NewLink Genetics Corporation stock can currently be purchased for approximately $7.29.